BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Mar 27, 2019
Translation in Brief

A mitochondrial shield from cell death

An IBM-Mount Sinai team has challenged the prevailing idea that high mitochondrial counts in tumor cells enhance cancer’s sensitivity to apoptosis-inducing therapies by showing that low numbers of the organelle actually do the trick. The...
BC Week In Review | May 26, 2017
Clinical News

AbbVie starts Phase I for TRAIL-receptor agonist in cancer

Apogenix AG (Heidelberg, Germany) said partner AbbVie Inc. (NYSE:ABBV) began a Phase I trial to evaluate ABBV-621 (APG880) in 92 patients with relapsed or refractory solid tumors, non-Hodgkin’s lymphoma (NHL) or acute myelogenous leukemia (AML)....
Items per page:
1 - 3 of 3